AMPLIA THERAPEUTICS LIMITED

INVESTOR PRESENTATION - AMPLIA THERAPEUTICS LIMITED

Announcements
announcementt+2 movementdate
Market Data

Current Price

$0.125

52WK HIGH

$0.24

52WK LOW

$0.045

1YR RETURN

+40.45%

1YR RETURN VS. SECTOR

+3.39%

90 DAY RETURN

+50.60%

ASX RANK

1,506

/2,032

SECTOR RANK

40

/47

SHARES OUTSTANDING

106.34m
ASX:ATX

AMPLIA THERAPEUTICS LIMITED

Health Care

Amplia Therapeutics Limited (ASX:ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Amplia has two core patent families over its FAK assets. Their ideology is that FAK is an increasingly important target in the field of cancer immunology and that FAK inhibition has the potential to sensitize treatment-resistant cancers to the existing chemotherapeutics. With FAK in mind, Amplia has a particular development focus in pancreatic and ovarian cancer.

Read more

Market Cap

13.29m

Price at Close

$0.125

4w avg. Volume

563.34k

4w avg. Turnover

$82.90k

ASX:ATX is not raising right now

Want to invest?

Fresh Equities
Support

Ask Fresh

Archive
Contact Us

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

(03) 9028 2888

deals@freshequities.com